Navigation Links
Ondine's CEO Carolyn Cross to be a Plenary Session Speaker at 14th World Congress of International Photodynamic Association
Date:5/14/2013

Vancouver, British Columbia (PRWEB) May 14, 2013

Ondine Biomedical Inc. announces that its CEO, Carolyn Cross, will be a Plenary Session Speaker at the World Congress of the of the International Photodynamic Association (IPA) on May 28th through May 31st, 2013. Carolyn Cross will be representing the field of work in Photodisinfection (also known as antimicrobial Photodynamic Therapy or aPDT). Ondine Biomedical is the global leader in the design and development of Photodisinfection based therapies, and is involved with all aspects of technology, product and clinical development through to commercialization of photodisinfection products. Photodisinfection based applications under development at Ondine include products for the dental, hospital acquired infection prevention (VAP, SSI, UTI, Blood Catheter, GI) and chronic sinusitis markets. Ms. Cross stated her speech will provide an “excellent opportunity to talk about the advances Ondine has made in Photodisinfection in a variety of applications and the larger implications those advances represent for Photodynamic technology.”

The IPA World Congress is a biannual conference highlighting the advances in scientific and clinical research around the world. This year's Congress is being held May 28th to May 31st, 2013 at the Ritz-Carlton Hotel, Seoul, Korea. All of the leaders in the field of PDT and their work will be represented during this event. Clinicians, scientists, researchers, hospital administrators, students are welcome to participate at this year's conference. Registration details are available here: IPA Registration

About the International Photodynamic Association

The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy (PDT) and photodiagnosis (PD). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT

About Carolyn Cross:

Carolyn Cross is the founder and CEO of Ondine Biomedical Inc., formed in 1999, and has over 18 years of direct experience working with early stage companies and has 25 years of experience with public market securities. Previously, Carolyn was responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. Carolyn is currently a member of the Women’s Presidents Organization, the International Women’s Forum, the Toronto Society of Financial Analysts, the Courthill and Cherie Blair Foundations, and the Association for Professionals in Infection Control and Epidemiology. Carolyn Cross is the Founder of OrGenX Biopharma Corporation, a WEConnect certified company.

Read the full story at http://www.prweb.com/releases/papdt/WorldCongress/prweb10728611.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
2. NASA develops super-black material that absorbs light across multiple wavelength bands
3. Micross Components Hosts Stop on "Drive for Innovation" Tour
4. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
5. Autism mutations, scattered across many genes, merge into common network of interactions
6. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
7. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
8. Albany CrossFit Wins Competition By Raising $32,579 For St. Jude Children's Research Hospital
9. Its Indiana State Fair Season: New BioCrossroads Report Emphasizes Opportunities in Food and Agriculture Innovation
10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
11. CureLauncher is a New Website That Connects Patients to Trials Across the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
Breaking Biology News(10 mins):